

# Using Machine Learning to Assess Potential Cases of Transthyretin Cardiac Amyloidosis in Brazil: A Retrospective Database Approach

Isabella Zuppo Laper<sup>1</sup>; Cecilia Camacho-Hubner<sup>2</sup>; Rafaela Vansan Ferreira<sup>1</sup>; Claudenice Leite Bertoli de Souza<sup>2</sup>; Marcus Vinícius Simões<sup>3</sup>; Fabio Fernandes<sup>4</sup>; Edileide de Barros Correia<sup>5</sup>; Ariane de Jesus Lopes de Abreu<sup>1</sup> and Guilherme Silva Julian<sup>2</sup>

<sup>1</sup>IQVIA Brazil; <sup>2</sup>Rare Disease, Pfizer, New York USA and Pfizer Brazil; <sup>3</sup>Division of Cardiology, USP School of Medicine in Ribeirão Preto. Amyloidosis Research Center at HC-FMRPUSP; <sup>4</sup>Cardiomyopathies Group at InCor HC-FMU-SP; <sup>5</sup>Division of Cardiology at FMUSP; <sup>6</sup>Amyloidosis Center of Instituto Dante Pazzanese de Cardiologia, Sao Paulo, Brazil



## Introduction

- Amyloidosis is a group of protein misfolding disorders leading to organ damage due to insoluble amyloid fibril deposits
- The two primary types of cardiac amyloidosis are light-chain amyloid (AL) and transthyretin (TTR) cardiac amyloidosis
- TTR amyloidosis can be hereditary (hATTR) or age-related (wtATTR). It is an often-overlooked cause of heart failure in older adults
- Recent studies reveal its prevalence in various patient groups: up to 13% in HFpEF, 16% in aortic stenosis patients undergoing valve replacement, 7-8% in carpal tunnel release surgery, and 17% in some other contexts
- ATTR-CM is significant in the context of cardiovascular diseases, a leading global cause of death.

## Objective

- This study aimed to identify and describe the profile of potential transthyretin cardiac amyloidosis (ATTR-CM) cases in the Brazilian public health system (SUS), using a predictive machine learning (ML) model.

## Materials and Methods

- This was a retrospective descriptive database study that aimed to estimate the frequency of potential ATTR-CM cases in the Brazilian public health system (Figure 1) using a supervised machine learning (Figure 2) model, with data extracted from DATASUS outpatient and inpatient datasets from January 2015 to December 2021
- To build the model, a list of ICD-10 codes and procedures potentially related with ATTR-CM was created based on literature review and validated by experts (Figure 3)

Figure 1. Study Design Summary




Figure 2. Machine Learning Approach





Figure 3. Study Flow Diagram



## Results

- From 2015 to 2021, the ML model classified 262 hATTR-CM (213 reference hATTR-CM and 49 hATTR-CM-like) and 1,581 wtATTR-CM (203 reference wtATTR-CM and 1,378 wtATTR-CM-like). Overall, the median age of hATTR-CM and wtATTR-CM patients was 66.8 and 59.9 years, respectively
- The ICD-10 codes most presented as hATTR-CM and wtATTR-CM were related to heart failure and arrhythmias, with similar procedures performed (Figure 4). Regarding healthcare utilization, hATTR-CM and hATTR-CM-like had similar profiles on proportion of patients with outpatient visits (hATTR-CM 98.0% vs. 92.0% hATTR-CM-like) and different profile related to proportion of hospitalized patients (hATTR-CM 94.4% vs. 32.7% hATTR-CM-like) (Figure 5)
- In wtATTR-CM groups, although both proportions on outpatient visits and hospitalizations were similar, the length of stay (LOS) on hospitalizations was different in wtATTR-CM-like (wtATTR-CM median LOS 5.0 [IQR:2.0 - 10.0] vs. median LOS 7.0 [IQR:3.0 - 14.0])

Figure 4. Most common procedures per cohort





Figure 5. Hospitalization rate for wt- and hATTR-CM



## Conclusions

- Our findings may be useful to support decreasing the uncertainties on ATTR-CM population size in Health Technology Assessment appraisals and in the development of healthcare guidelines and policies to address patients' unmet needs and to improve early diagnosis and access to treatment for patients with ATTR-CM in Brazil
- This study puts a spotlight on the ATTR-CM underdiagnosis in Brazil using a machine learning approach, which can be used as an important tool to support diagnosis improvement.

## Acknowledgements

- This study was sponsored by Pfizer
- All authors contributed to the abstract conception and design
- We thank Luciana Piton and Valdehi Wadhwa for their support with medical writing

## References

Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019 Jun;73(22):2872–91; Castano A, Narotsky DL, Hamid N, Khaliq OK, Morgenstern R, DeLuca A, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–87; Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72(17):2040–50.

The image used in the title has been taken from Freepik